Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
New outcomes study for ticagrelor (BRILINTA™) to examine longer-term treatment for post- ACS patients
-
AstraZeneca initiates phase III clinical development of fostamatinib for the treatment of rheumatoid arthritis
-
Results of Zibotentan Phase III trial in castration resistant prostate cancer
-
52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
-
BRILIQUE (ticagrelor) receives positive opinion from European CHMP for the treatment of Acute Coronary Syndromes
-
US and EU regulatory submissions for VANDETANIB in advanced medullary thyroid cancer accepted for review
-
24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus
-
US Food and Drug Administration Extends Review Timeline For BRILINTA (Ticagrelor) New Drug Application
-
European Commission Issues Positive Decision for Approval of Seroquel XR as an Add-On Treatment of Major Depressive Disorder
-
MedImmune receives complete response letter on motavizumab
Latest articles and press releases
All of our latest press releases and articles are available to explore
